5.3 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | intake_tier | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | Q1 2026 in Review: GLP-1 RAs for Psychiatric Practice — Psychopharmacology Institute | Psychopharmacology Institute | https://psychopharmacologyinstitute.com/publication/q1-2026-in-review-milsaperidone-glp-1-ras-and-zuranolone/ | 2026-04-01 | health | article | unprocessed | high |
|
research-task |
Content
The Psychopharmacology Institute is a widely used CME (continuing medical education) platform for psychiatrists and mental health prescribers. This Q1 2026 review covers three major psychopharmacology developments: milsaperidone approval, GLP-1 RAs in psychiatric practice, and zuranolone.
On GLP-1 RAs in Psychiatric Practice — Key Clinical Guidance:
1. FDA suicidality warning removal (January 2026):
- FDA requested manufacturers remove suicidal ideation and behavior (SI/B) warning from GLP-1 RA labeling
- Warning was carried over from postmarketing reports of older weight-loss medications — NOT based on GLP-1-specific data
- FDA's comprehensive review found no increased risk of suicidal ideation, anxiety, depression, or psychosis
- Clinical implication: "Patients can be reassured the FDA found no increased risk of suicidal ideation and behavior after a comprehensive review"
2. Psychiatric benefit evidence cited:
- Lancet Psychiatry Swedish cohort: semaglutide → 42% lower risk of worsening mental illness (vs. same patients' non-use periods); liraglutide → 18% lower risk
- Data source: within-individual design (n=95,490 with pre-existing depression/anxiety)
3. Schizophrenia-specific guidance (separate companion article):
- Priority population: patients on clozapine or olanzapine who cannot easily switch treatment
- Metabolic screening: hemoglobin A1c cutoff 5.4% for early-stage metabolic risk targeting (preventative threshold, below the 5.7% prediabetes cutoff)
- Rationale: antipsychotic-induced weight gain and metabolic syndrome are common; GLP-1 addresses metabolic risk while patients remain on necessary antipsychotics
4. Monitoring protocol:
- Monthly check-ins using validated depression/suicidality tools
- Psychoeducation for patients and caregivers: mood lability, appetite changes, suicidal ideation
Significance of source: Psychopharmacology Institute represents de facto clinical guidance infrastructure for psychiatrists in the US. No formal APA clinical practice guideline on GLP-1 exists as of Q1 2026. This review is the primary channel through which psychiatrists are learning prescribing guidance. ~60 hours ABOM certification is the formal path; this CME is the informal path.
Agent Notes
Why this matters: This is the closest thing to a formal psychiatric professional society position on GLP-1 as of May 2026 — not an APA guideline, but a widely used CME platform's structured clinical review. The Psychopharmacology Institute's guidance is what many US psychiatrists will use in practice. The 5.4% HbA1c screening threshold for schizophrenia patients is a specific, actionable claim.
What surprised me: The focus on schizophrenia/clozapine/olanzapine patients as the priority population is narrower than I expected. The guidance isn't "prescribe GLP-1 for psychiatric indications" — it's "manage metabolic side effects of antipsychotics using GLP-1." This is a much more conservative framing than Osmind's "GLP-1 is a psychiatric drug" argument.
What I expected but didn't find: Any guidance on GLP-1 for SUD (despite the JAMA Psychiatry AUD RCT evidence being available by Q1 2026). The Institute's guidance doesn't include addiction medicine applications — suggesting professional society guidance lags clinical evidence by ~1 year.
KB connections:
- value-based care transitions stall at the payment boundary — reimbursement for GLP-1 in psychiatric indications is not addressed in this guidance because CMS/payers have not yet created psychiatric GLP-1 reimbursement codes
- the mental health supply gap is widening not closing — this guidance serves the already-served: psychiatrists who use CME platforms; the competency gap in primary care prescribers goes unaddressed
Extraction hints:
- Claim: "Psychiatry is addressing GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines, creating uneven competency distribution across the prescriber population" — Belief 3 instance
- The 5.4% HbA1c threshold for schizophrenia/antipsychotic patients is a specific monitoring claim
- The FDA suicidality warning removal is already captured in Session 37 sources — check for duplicates before extracting
Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk WHY ARCHIVED: Represents the state of formal clinical guidance on GLP-1 in psychiatry as of Q1 2026 — de facto guidance through CME, not formal society guidelines. Documents the structural gap in competency infrastructure. EXTRACTION HINT: The gap between "SUD evidence available in JAMA Psychiatry" and "SUD not mentioned in Psychopharmacology Institute Q1 guidance" is itself a claim about evidence-to-practice lag time — approximately 1 year based on this data point.